Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nextage TherapeuticsXTAE:NXTG 8 PB Ratio is 2.23 as of Aug. 08, 2026, which is 24% below its 10-year median of 2.95. GuruFocus rates XTAE:NXTG with a GF Score™ of 8/100 and a GF Value™ of ₪0.31 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 921 Drug Manufacturers companies, Nextage Therapeutics ranks worse than 55.59% on this metric.
Nextage Therapeutics Ltd stock PB Ratio (=2.25) is close to 5-year low of 2.06.
The historical rank and industry rank for Nextage Therapeutics's PB Ratio or its related term are showing as below:
XTAE:NXTG'
s PB Ratio Range Over the Past 10 Years
Min: 1.67 Med: 2.95 Max: 96.96
Current: 2.18
During the past 10 years, Nextage Therapeutics's highest PB Ratio was 96.96. The lowest was 1.67. And the median was 2.95.
XTAE:NXTG's PB Ratio is ranked worse than 55.59% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.96
vs XTAE:NXTG: 2.18
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Nextage Therapeutics was 80.90% per year. The lowest was -290.80% per year. And the median was -0.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Nextage Therapeutics PB Ratio Related Terms
Nextage Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Nextage Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nextage Therapeutics PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nextage Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Nextage Therapeutics (XTAE:NXTG) has a PB Ratio of 2.23 as of Aug. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nextage Therapeutics and its competitors. This is 24% below median its historical median of 2.95. Over the past decade, Nextage Therapeutics' PB Ratio has ranged from 1.67 to 96.96. According to the industry distribution chart, Nextage Therapeutics ranks #512 out of 921 companies in the Drug Manufacturers industry, placing it in the top 55.6%.
Is Nextage Therapeutics' PB Ratio too high?
Nextage Therapeutics' current PB Ratio of 2.23 is 24% below median its 10-year median of 2.95. Over the past 10 years, this metric has ranged from a low of 1.67 to a high of 96.96. The Drug Manufacturers industry median PB Ratio is 1.96. Nextage Therapeutics' value of 2.23 is 13.8% above this industry median. Based on the distribution chart, Nextage Therapeutics ranks #512 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Nextage Therapeutics has a GF Score™ of 8/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nextage Therapeutics' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nextage Therapeutics ranks #512 out of 921 companies for PB Ratio. This places Nextage Therapeutics in the lower half of its industry. The industry median PB Ratio is 1.96. Nextage Therapeutics' value of 2.23 is 13.8% above this benchmark. Historically, Nextage Therapeutics' own PB Ratio has ranged from 1.67 to 96.96 over the past decade. While the company's 10-year median is 2.95 vs. the industry median of 1.96, Nextage Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nextage Therapeutics's current PB Ratio of 2.23 is 13.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nextage Therapeutics and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nextage Therapeutics's current PB Ratio is 2.23, which is 24% below median its own 10-year median of 2.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextage Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nextage Therapeutics (XTAE:NXTG) is currently considered Modestly Overvalued. The stock's GF Value™ is ₪0.31, compared to a current price of ₪0.39 — trading 25.8% above its estimated fair value. The current PB Ratio is 2.23, which is 24% below median its 10-year median of 2.95 and 13.8% above the Drug Manufacturers industry median of 1.96. Nextage Therapeutics' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Nextage Therapeutics (XTAE:NXTG), the current PB Ratio is 2.23 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nextage Therapeutics (XTAE:NXTG) Overvalued in 2026?
Based on GuruFocus' analysis, Nextage Therapeutics stock appears to be overvalued.
The current stock price of ₪0.39 is trading 25.8% above its estimated GF Value™ of ₪0.31.
GuruFocus considers Nextage Therapeutics to be Modestly Overvalued.
Key valuation signals for XTAE:NXTG:
PB Ratio: 2.23 (24% below median its 10-year median of 2.95)
GF Value™: ₪0.31 vs. price of ₪0.39 (25.8% above fair value)
Industry Position: 13.8% above the Drug Manufacturers median (#512 of 921)
No single metric tells the full story. See the XTAE:NXTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.
8GF Score
Get the complete analysis for XTAE:NXTG
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:NXTG has been successfully added to your 
